MedPath

Exploratory research on effectiveness and safety of Rituximab treatment for steroid intractable pemphygus, bullous pemphigoid and epidermolysis bullosa acquisita.

Phase 2
Conditions
pemphigus, bullous pemphigoid, epidermolysis bullosa acquisita
Registration Number
JPRN-UMIN000004428
Lead Sponsor
Research group of rare intractable dermatologial disorder
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Health condition 1) Pregnancy 2) Allergy for biologics 3) Severe organ disorder 4) History of other diseases which need systemic steroid treatment 5) Infections 6) Malignancy Treatment history 1) Use of biologics 2) Severe adverse events by immunosuppressant (CTCAE over grade 3)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1) A rate of severe adverse events, beyond CTCAE grade 3. 2) A rate of remission
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath